Drugs / TAS-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00166543 | May 2004 → Jan 2008 | breast cancer | SRI International | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00166543 ↗ |
| Known as | HLX-801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545211 ↗ |
| Known as | SR-16234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545211 ↗ |
| Known as | Tas-108 citrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545211 ↗ |
| Action | Inhibit | “Estrogen receptor alpha antagonist” CHEMBL3545211 ↗ |
| Modality | Small molecule | — CHEMBL3545211 ↗ |
| Route | Oral | “TAS-108 Administered Orally” NCT00166543 ↗ |
| Target | ESR1 | “Estrogen receptor alpha antagonist” CHEMBL3545211 ↗ |